Novel immunomodulating and immunotherapies, and novel therapies and strategies for inflammatory arthropathy.
During the past year, another disease possibly influenced by intravenous gammaglobulin was identified as dermatomyositis/polymyositis. Additional studies provided further information regarding the use of monoclonal anti-CD4 antibody and combination therapy in rheumatoid arthritis, antithymocyte globulin in scleroderma, and intravenous gammaglobulin in juvenile rheumatoid arthritis. New therapeutic horizons also emerged including the novel immunosuppressant FK-506, the removal of disease incitants by medical arthroscopy, antiarthritic T-cell receptor V beta-specific antibodies, and the potential of achieving tolerance via peroral administration of autoantigens.
Trentham
D E
DE
Harvard Medical School, Boston, Massachusetts.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D001168:Arthritis / Q000188:drug therapy*; D006801:Humans; D007167:Immunotherapy
D000276:Adjuvants, Immunologic